Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Hsiao, Chuan Yu ^a   Chiu, Hsien Yi ^a   Wang, Ting Shun ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; ISONIAZID; METHOTREXATE; TUBERCULOSTATIC AGENT; USTEKINUMAB; DERMATOLOGICAL AGENT; GAMMA INTERFERON;

ADULT; ARTICLE; DISEASE BURDEN; FEMALE; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRESCRIPTION; PREVALENCE; PSORIASIS; RETROSPECTIVE STUDY; SCREENING TEST; SEROCONVERSION; TAIWAN; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; INTERFERON GAMMA RELEASE ASSAY; MIDDLE AGED; PROCEDURES; TUBERCULIN TEST;

ADULT; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULIN TEST; USTEKINUMAB;

EID: 85029378674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0184178     Document Type: Article

References (34)

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104. https://doi.org/10.1056/NEJMoa011110 PMID: 11596589
2. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122–2127. https://doi.org/10.1002/art.11137 PMID: 12905464
3. Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39: 295–299. https://doi.org/10.1086/421494 PMID: 15306993
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285. https://doi.org/10.1001/jama.295.19.2275 PMID: 16705109
5. Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. (2015) To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 73: 420–428.e1. https://doi.org/10.1016/j.jaad.2015.06.004 PMID: 26184440
6. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, et al. (2013) Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 44: 121–140. https://doi.org/10.1007/s12016-012-8301-7 PMID: 22311162
7. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. (2004) Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170: 59–64. https://doi.org/10.1164/rccm.200402-179OC PMID: 15059788
8. Lein AD, von Reyn CF, Ravn P, Horsburgh CR Jr, Alexander LN, Andersen P. (1999) Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 6: 606–609. PMID: 10391871
9. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. (2008) Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177: 1164–1170. https://doi.org/10.1164/rccm.200711-1613OC PMID: 18276940
10. Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, et al. (2014) Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol 171: 884–890. https://doi.org/10.1111/bjd.13130 PMID: 24863903
11. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59: 800–806. https://doi.org/10.1002/art.23705 PMID: 18512714
12. Pratt A, Nicholl K, Kay L. (2007) Use of the QuantiFERON TB Gold test as part of a screening pro-gramme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 46: 1035–1036. https://doi.org/10.1093/rheumatology/ kem064 PMID: 17409126
13. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35: 776–781. PMID: 18398944
14. Matulis G, Jüni P, Villiger PM, Gadola SD. (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67: 84–90. https://doi.org/10.1136/ard.2007.070789 PMID: 17644549
15. Chiu HY, Hsueh PR, Tsai TF. (2011) Clinical experience of QuantiFERON® -TB Gold testing in patients with psoriasis treated with tumor necrosis factor blockers in Taiwan. Br J Dermatol 164: 553–559. https://doi.org/10.1111/j.1365-2133.2010.10137.x PMID: 21083541
16. Cheng CY, Hui CY, Sindy Hu, Hsieh MH, Huang YH. (2015) Serial QuantiFERON-TB Gold In-Tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy. Dermatol Sinica 33: 124–129.
17. Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY, et al. (2011) Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 31: 271–278. https://doi.org/10.3343/kjlm.2011.31.4.271 PMID: 22016681
18. Garcovich S, Ruggeri A, D’Agostino M, Ardito F, De Simone C, Delogu G, et al. (2012) Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 26: 1572–1576. https://doi.org/10.1111/j.1468-3083.2011.04220.x PMID: 21923840
19. Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, et al. (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74: 1848–1853. https://doi.org/10.1136/annrheumdis-2014-205376 PMID: 24854354
20. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. (2013) Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment. J Infect 66: 346–356. https://doi.org/10.1016/j.jinf.2012.10.017 PMID: 23103667
21. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63: 154–163. https://doi.org/10.1016/j.jdermsci.2011.05.005 PMID: 21741220
22. Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. (2006) Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 18: 347–361. https://doi.org/10.1016/j.smim.2006.07.010 PMID: 16997570
23. Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. (2012) The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 167: 1145–1152. https://doi.org/10.1111/j.1365-2133.2012.11142.x PMID: 22803615
24. Errichetti E, Piccirillo A. (2014) Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol 24: 508–509. https://doi.org/10.1684/ejd.2014.2386 PMID: 25120233
25. Saraceno R, Specchio F, Chiricozzi A, Sarmati L, Amicosante M, Chimenti MS, et al. (2014) Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. Expert Opin Biol Ther 14: 151–156. https://doi.org/10.1517/14712598.2014.860441 PMID: 24303977
26. Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, et al. (2013) Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. Br J Dermatol 169: 1133–1140. https://doi.org/10.1111/bjd.12544 PMID: 23909256
27. Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. (2010) Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 37: 413–425. https://doi.org/10.1111/j.1346-8138.2010.00802.x PMID: 20536646
28. Feng CG, Jankovic D, Kullberg M, Cheever A, Scanga CA, Hieny S, et al. (2005) Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174: 4185–4192. PMID: 15778379
29. Tsai TF, Chiu HY, Song M, Chan D. (2013) A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 168: 444–446. https://doi.org/10.1111/j.1365-2133.2012.11162.x PMID: 22816505
30. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 71: 231–237. https://doi.org/10.1136/annrheumdis-2011-200489 PMID: 22021896
31. Scrivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, Iaiani G, et al. (2013) Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 40: 157–165. https://doi.org/10.3899/jrheum.120688 PMID: 23204217
32. Mancuso JD, Bernardo J, Mazurek GH. (2013) The elusive "gold" standard for detecting Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 187: 122–124. https://doi.org/10.1164/rccm.201211-2033ED PMID: 23322793
33. Powell RD 3rd, Whitworth WC, Bernardo J, Moonan PK, Mazurek GH. (2011) Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests. PLoS One 6: e20061. https://doi.org/10.1371/journal.pone.0020061 PMID: 21687702
34. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. (2013) Association between traditional systemic anti-psoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol 69: 25–33. https://doi.org/10.1016/j.jaad.2012.12.966 PMID: 23375515